Valuation : Design Therapeutics, Inc.

Market Cap 976M 837M 786M 718M 1.35B 93.06B 1.36B 9.3B 3.6B 46.95B 3.66B 3.58B 155B P/E 2026 *
-11.4x
P/E 2027 * -9.73x
Enterprise Value 999M 858M 805M 735M 1.39B 95.33B 1.39B 9.53B 3.69B 48.09B 3.75B 3.67B 159B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
68.13%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Design Therapeutics, Inc.

1 day-0.55%
1 week+0.06%
Current month+27.83%
1 month+31.06%
3 months+40.27%
6 months+49.14%
Current year+65.99%
1 week 14.64
Extreme 14.64
15.96
1 month 11.45
Extreme 11.45
16.12
Current year 8.23
Extreme 8.23
17.25
1 year 5.1
Extreme 5.095
17.25
3 years 1.96
Extreme 1.96
17.25
5 years 1.94
Extreme 1.94
26.3
10 years 1.94
Extreme 1.94
50.5
Manager TitleAgeSince
Chief Executive Officer 56 2023-08-24
Chief Tech/Sci/R&D Officer 60 2025-04-16
Chief Tech/Sci/R&D Officer - 2025-01-31
Director TitleAgeSince
Chairman 56 2017-12-17
Director/Board Member 71 2019-06-30
Director/Board Member 49 2020-01-31
Date Insider Type Main position Quantity % Market Cap.
1/2/26 Free

Chief Executive Officer

750,000 1.3166%
1/2/26 Free

Director

45,000 0.0790%
1/2/26 Free

Controller/Auditor

150,000 0.2633%
Change 5-day change 1-year change 3-year change Capi.($)
-0.55%+0.06%+194.33%+607.73% 976M
-0.05%+0.20%+2.55%+23.45% 50.96B
+1.23%+2.71%+471.71%+574.15% 46.18B
-0.69%+1.46%+24.79%+85.34% 42.73B
+0.90%+2.96%+39.63%+18.86% 43.04B
-2.27%-3.02%+14.22%+51.50% 33.48B
+0.02%+1.00%+30.69%+136.49% 17.28B
-0.62%-2.48% - - 16.43B
-0.19%-0.14%+11.60%+28.39% 14.73B
+2.27%+3.70%+85.65%+52.06% 14.09B
Average +0.01%+0.98%+97.24%+175.33% 27.99B
Weighted average by Cap. +0.03%+1.15%+103.43%+144.20%

Financials

2026 *2027 *
Net sales - -
Net income -86.04M -73.85M -69.32M -63.31M -119M -8.21B -120M -820M -318M -4.14B -323M -316M -13.71B -115M -98.71M -92.65M -84.62M -160M -10.97B -160M -1.1B -425M -5.53B -432M -422M -18.33B
Net Debt 23.81M 20.44M 19.18M 17.52M 33.07M 2.27B 33.22M 227M 87.98M 1.15B 89.41M 87.47M 3.79B -295M -253M -238M -217M -410M -28.15B -412M -2.81B -1.09B -14.2B -1.11B -1.08B -47.03B
Logo Design Therapeutics, Inc.
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Employees
55
Date Price Change Volume
26-08-27 US$15.57 -0.13% 100,663
26-08-26 US$15.59 -0.57% 718,728
26-08-25 US$15.68 +2.95% 608,109
26-08-24 US$15.23 +1.60% 408,654
26-08-21 US$14.99 -3.66% 552,135
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
15.59USD
Average target price
21.00USD
Spread / Average Target
+34.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DSGN Stock